Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Caelyx in breast cancer patients with brain metastases not eligible for anti-HER2 therapy
2007-006790-81Phase 2Active
- Sponsor
- APREC
- Start
- Jun 2008
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, brain metastases and central nervous system metastases, sponsored by APREC. Primary endpoint: Local response rate (brain/CNS lesions). Started Jun 2008; status: active.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancerbrain metastasescentral nervous system metastases
Beyond the preview
Go deeper on 2007-006790-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006790-81.